

# RECOMBINANT VSV VECTOR FOR COVID-19 VACCINE OR DRUG SCREENING

---

[Rothlauf, Paul, Whelan, Sean](#)

[Miller, Qian](#)

T-019338

**Background:** Recombinant vesicular stomatitis virus (VSV) has successfully been used to create a vaccine for Ebola virus that is currently on the market. Previously, Professor Sean Whelan and colleagues have exploited the VSV platform to create similar vectors for both SARS and MERS.

**Technology:** The Whelan Lab has now genetically engineered a potential VSV vaccine candidate for COVID-19 by replacing the single viral envelope glycoprotein (G) of VSV with a modified version of the spike protein (S) of SARS-CoV-2. This replication-competent chimeric VSV-SARS-CoV2 virus has demonstrated immunogenicity and efficacy in mice with high titers of neutralizing antibodies. Overall, it protects against severe SARS-CoV-2 infection and lung disease, supporting its further development as an attenuated vaccine with the potential for low-cost manufacturing.

In addition, a related GFP-VSV reporter construct could be used as a screening platform for COVID-19 drug candidates (e.g., new antibody therapies or small molecule entry inhibitors).

## **In vivo efficacy in mice:**

- **High titers:**

- the recombinant virus produces high titers of neutralizing antibodies that target both the SARS-CoV-2 spike protein and the receptor binding domain subunit
- median and mean serum neutralizing titers of greater than 1/5,000
- two doses induced higher neutralizing titers (1/2,700,000) with more rapid onset

- **Protection:**

- immunized mice challenged with human SARS-CoV-2: had profoundly reduce viral infection; had decreased induction of pro-inflammatory cytokines; and were protected from lung inflammation and viral pneumonia
- passive transfer of sera from immunized mice protected naïve mice (decreased viral burden and lung inflammation)

- **Research in progress** includes experiments on non-human primates.

## **Value proposition**

- **Robust response:**

- strong neutralizing antibody responses which are boosted by a second dose
- protects against infection, inflammation and pneumonia

- **Potential for simple, large-scale manufacturing:** grows efficiently in mammalian cell culture with high titers (e8 infectious units per ml in Vero cells) which could provide a cost-efficient and effective route for vaccine development

- **Advantages of VSV Vaccine Platform:**

- established efficacy in humans with Ebola vaccine
- stimulates both humoral and cellular immunity
- little pre-existing human immunity

- **Related reporter construct** that could be used to screen for therapeutics

**Publications:**

- Case, J. B., Rothlauf, P., Chen, R. E., Kafai, N., Fox, J. M., Shrihari, S., ... & Bloyet, L. M. (2020). [Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis](#). bioRxiv.
- Case, J. B., Rothlauf, P. W., Chen, R. E., Liu, Z., Zhao, H., Kim, A. S., ... & Ilagan, M. (2020). [Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2](#).

**Patent status:** Application filed

**Related Web Links:** [Sean Whelan profile](#)